|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date05 May 1992 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
自体肿瘤浸润淋巴细胞注射液(GT201注射液)治疗晚期实体瘤的I/II期临床研究
[Translation] Phase I/II clinical trial of autologous tumor-infiltrating lymphocyte injection (GT201 injection) for the treatment of advanced solid tumors.
Ⅰ期试验:
主要研究目的
评价GT201 注射液在复发或转移性的实体瘤治疗中的安全性和耐受性。
次要研究目的
评价GT201 注射液在复发或转移性的实体瘤治疗中的有效性;
监测GT201注射液在复发或转移性的实体瘤治疗中的PK。
[Translation] Phase I Trial:
Primary Study Objective:
Evaluate the safety and tolerability of GT201 injection in the treatment of recurrent or metastatic solid tumors.
Secondary Study Objectives:
Evaluate the efficacy of GT201 injection in the treatment of recurrent or metastatic solid tumors;
Monitor the pharmacokinetic (PK) profile of GT201 injection in the treatment of recurrent or metastatic solid tumors.
100 Clinical Results associated with Suzhou Gravel Biotechnology Co., Ltd.
0 Patents (Medical) associated with Suzhou Gravel Biotechnology Co., Ltd.
100 Deals associated with Suzhou Gravel Biotechnology Co., Ltd.
100 Translational Medicine associated with Suzhou Gravel Biotechnology Co., Ltd.